As a result of evidence that second respiratory infections with Coccidioides immitis rarely, if ever, occur in nature (Smith, 1957) , and that dissemination beyond the regional lymph nodes is extremely rare in naturally or laboratory-acquired primary cutaneous coccidioidomycosis
the protective effect of the viable vaccine. All animals receiving both vaccines developed mild pulmonary coccidioidomycosis, whereas only 50% of the animals receiving only the viable vaccine were infected. In addition, the group receiving both vaccines demonstrated a more rapid and higher postchallenge precipitin titer. All vaccinated animals (those receiving the killed, the viable, or a combination of the two vaccines) survived for 4 months after challenge, as compared with 88% mortality (50% within 14 days) in the nonvaccinated controls.
As a result of evidence that second respiratory infections with Coccidioides immitis rarely, if ever, occur in nature (Smith, 1957) , and that dissemination beyond the regional lymph nodes is extremely rare in naturally or laboratory-acquired primary cutaneous coccidioidomycosis (Wilson, Smith, and Plunkett, 1953; Guy and Jacobs, 1926; Trimble and Doucette, 1956; Wright, Newcomer, and Nelson, 1959; Johnson et al., 1964; Meis, 1961; Winn, 1961 Winn, , 1964 Harrell and Honeycutt, 1963; Goodman and Schabarum, 1963) , studies on a viable vaccine against coccidioidomycosis were initiated. Previous studies of such a vaccine by Pappagianis et al. (1959) and Converse et al. (1962a) in mice, and by Pappagianis et al. (1960) in cynamolgus monkeys, had indicated the feasibility of this method of protection against the disease.
It was reported (Converse, Castleberry, and Snyder, 1961) that: (i) protection against pulmonary challenge with C. immitis could be obtained in rhesus monkeys by subcutaneous injection of 10 viable arthrospores; (ii) that this protection was not strain-specific; and (iii) that no dissemination beyond the regional lymph nodes occurred with a vaccine dose of this size. It was noted, however, that in some instances (particularly in the higher vaccine doses) untoward tissue reactions (ulcerated vaccination site and axillary lymphadenopathy) resulted from the injection of the viable vaccine. We indicated (Converse et al., 1962b ) that various strains of C. immitis, used as viable vaccines, exhibited substantial differences in tissue reactions to inoculation, and (Castleberry, Converse, and Soto, 1964) Serology. Serological response of the animals to the vaccines and to the respiratory challenge was followed by the agar-gel immuno-diffusion precipitin test of Ray and Kadull (1964) and by the complement-fixation test.
Skin hypersensitivity. Coccidioidin skin tests were administered intrapalpebrally. The coceidioidin was prepared by growing arthrospores for 7 days at 34 C with shaking in the liquid medium of Goldschmidt and Taylor (1958) . The cultures were then stored for 3 weeks at 5 C and Seitz filtered. The undiluted filtrate was used for the tests.
Histopathology. Tissues for histological study were fixed in 10% formaldehyde, impregnated with paraffin, sectioned, and stained with the Giemsa, Gomori silver methenamine, and Ziel-Nielson acid-fast stains.
Culture of histological material. Mycological cultures were made on glucose-peptone-yeast extract-agar slants of the right axillary lymph nodes, the lungs, and any suspicious lesions, for recovery of the fungus.
Four groups of monkeys (seven to nine in each group) were injected with the formaldehydekilled vaccine, the viable vaccine, the formaldehyde-killed vaccine followed by the viable vaccine, or were left unvaccinated as controls. All animals were observed, during the 6-month interval between the inoculatioin of the viable vaccine and the respiratory challenge, for development of ulceration of the vaccination site or axillary lymphadenopathy. Their serological response to the various vaceination regimens was also recorded. Similar observations were made for an additional 4-month period after respiratory challenge, to determine the efficiency of the vaccines, and then all animals were killed and complete necropsies were performed. Two additional groups of monkeys (total of 13), receiving either the viable vaccine or the formaldehyde-killed vaccine followed by the viable vaccine, were unchallenged by the respiratory rouite and were maintained for histological comparison. This control was also indicated by the serological response of these animals at 3 months postvaccination. As shown in Fig. 1 Table 2 , which can later be correlated with the histological findings: the higher the prechallenge titer (shown in the 0 column), the slower the development of the disease, as reflected by the acceleration of the postchallenge titer; and the lower the prechallenge titer, the greater the maximal titers developed after challenge. Note that the group receiving only the viable vaccine maintained its prechallenge titer until 60 days after challenge, in contrast to the other two groups, which exhibited an immediate rise in titer.
RESULTS
The clinical record of the experimental and control animals after challenge is shown in Table  3 . All animals receiving the viable vaccine (either with or without the killed vaccine) remained in good flesh and healthy in appearance and actions, throughout the 4-month observation period. Some apathy and poor appetite were noted among the group receiving only the killed vaccine, but otherwise they were healthy in appearance and appeared to recover from the effects of the challenge dose. As seen in the mortality column, all of the 24 vaccinated animals survived the respiratory challenge.
This was in striking contrast to the evidence of extremely severe illness in the nonvaccinated control animals. This group suffered an 88% mortal- (Table 3) correlated with the serological response and with clinical signs and symptoms. The seriousness of the disease increased stepwise in groups 1 through 4, as indicated by clinical symptoms, serological response, and extent of pathological involvement of the lungs. Although the mean maximal serological titer was the same (±1:4,096) for groups 2 and 3, the titers increased more rapidly in group 3 (see Table 2 ). The extent of lung involvement in infected animals in groups 1 and 2 was equal (+); however, approximately half the animals in group 1 were not infected (all animals in groups 2, 3, and 4 developed pulmonary coccidioidomycosis).
Histological sections from representative animals in each of the four groups are shown in Fig.  2 . Although lung sections in the first three groups appear similar, considerably more evidence of caseous necrosis may be noted in the center of the lesions in the lungs of animals in group 3 (receiving only the killed vaccine). Note, also, the almost complete destruction of lung tissue in the nonvaccinated control animals in group 4.
Although histological evidence indicated that 79% of the vaccinated, challenged animals (19 of 24) contracted pulmonary coccidioidomycosis, only 26% of these (5 of 19) exhibited positive lung cultures 4 months after exposure. As indicated by negative culture of the right axillary lymph nodes, 73% of the animals (22 of 30) receiving the viable vaccine were probably free from the vaccine strain at 10 months after vaccination.
Histological examination of the 13 vaccinated, unchallenged control monkeys revealed one animal with a generalized infection. Lesions containing the fungus were found in the lungs, liver, bronchial and axillary lymph nodes, and in the skin at the site of vaccination. Two other animals in this group showed minimal dissemination granulomata, in the pancreatic lymph node of one, and in the inguinal node of the other. No other lesions were found in either of these animals.
DISCUSSION
In ranking the effectiveness of the three vaccines used in this study, it appears, from the data presented here and particularly from former studies (Converse et al., 1961) , that the viable vaccine was the most effective, the combination of the killed and the viable next, and the killed vaccine least effective. This is borne out by the increasing indications of disease in the three groups of animals, in the order named above (clinical symptoms, serological response to pulmonary challenge including both height and acceleration of titer, and the pathological changes in the lungs).
The three disseminations of infection beyond the regional lymph nodes (axillary) noted in the vaccinated, unchallenged control animals must be attributed to the viable vaccine, since animalto-animal transmission of coccidioidomycosis is not known to occur. It should be noted, however, that a vaccine dose 15 times greater than necessary (Converse et al., 1961 ) and a particularly aggressive strain (D-76) of the fungus were used as the viable vaccine in this study. The high dose and the highly virulent strain were used in this instance so that any control of tissue reaction to its injection by the preinoculation of a killed vaccine would be absolutely clear-cut. It is thought, however, that the one generalized infection in the vaccinated, unchallenged groul) was a result of individual susceptibility of t-he monkey involved, since the fungus was still in evidence at the site of vaccination 10 months after injection. This has never occurred before in any of our studies; all other animals exhibited coml)lete healing of the vaccination site.
Production of a high degree of antibodies by injection of killed C. immitis has not been previously reported. It is thought that the relatively high titers and the unequivocally positive skintest reactions in the animals receiving only the killed vaccine were, in the present study, due to the use of incomplete Freund's adjuvant.
It is evident from the data presented that the viable vaccine can be controlled, by preinjection of a killed vaccine, to such an extent that the undesirable tissue reactions do not occur. However, it also appears that, to a certain extent, its protective effect was also impaired. Although the infectious dose of C. immitis received in nature is unknown, it is logical to believe that it would be more on the order of 2 or 3 to possibly 50 arthrospores, rather than 7,500 arthrospores as used in this study. It is hoped that a repetition of this experiment, with the use of a more realistic exposure dose (50 to 100 arthrospores) and a lower 
